AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26765630 — intervention group
Group type: COMPARATOR
Intervention: No-Mirror Training Group (NMG)
Number of subjects: 23
Study 24531602 — intervention group
Group type: COMPARATOR
Intervention: Conventional Drilling Method (CDM)
Number of subjects: 20
Study 24531602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo‐mechanical Caries Removal (CMCR)
Number of subjects: 20
Study 22374408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 (6·25, 25, 50, 100, or 200 mg)
Number of subjects: 426
Study 22374408 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (4 mg)
Number of subjects: 426
Study 22374408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 22374408 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 (all groups)
Number of subjects: 426
Study 22374408 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 426
Study 21111310 — intervention group
Group type: EXPERIMENTAL
Intervention: Photochromic IOL (Aurium Matrix acrylic, model 400)
Number of subjects: 118
Study 21111310 — intervention group
Group type: COMPARATOR
Intervention: Yellow IOL (AF-1)
Number of subjects: 118
Study 21111310 — intervention group
Group type: COMPARATOR
Intervention: Clear IOL (MC611MI)
Number of subjects: 118
Study 18519992 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential dental treatment (EDT) at 13 to 21 weeks' gestation
Number of subjects: 823
Study 18519992 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical or local anesthetics during root planing
Number of subjects: 823
Study 18519992 — intervention group
Group type: EXPERIMENTAL
Intervention: EDT and periodontal treatment
Number of subjects: 823
Study 18519992 — intervention group
Group type: EXPERIMENTAL
Intervention: EDT or periodontal treatment alone
Number of subjects: 823
Study 18519992 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 823
Study 16525811 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES) training for 8 weeks
Number of subjects: 9
Study 16525811 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining for 4 weeks after ES training
Number of subjects: 9
Study 12706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-strut ACS RX Multilink stent (strut thickness 50 microm)
Number of subjects: 611
Study 12706922 — intervention group
Group type: COMPARATOR
Intervention: Thick-strut BX Velocity stent (strut thickness 140 microm)
Number of subjects: 611
Study 12706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-strut ACS RX Multilink stent
Number of subjects: 611
Study 12706922 — intervention group
Group type: COMPARATOR
Intervention: Thick-strut BX Velocity stent
Number of subjects: 611
Study 12706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 611
Study 11015237 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb chest compression (TT)
Number of subjects: 21
Study 11015237 — intervention group
Group type: COMPARATOR
Intervention: Two-finger chest compression (TF)
Number of subjects: 21
Study 8647365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin treatment
Number of subjects: 13000
Study 8647365 — intervention group
Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 13000
Study 1595424 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviorally oriented work site program for weight control
Number of subjects: 0
Study 6369594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with DTIC and cyclophosphamide (600 mg/m2 administered intravenously every 3 weeks for nine cycles)
Number of subjects: 136
Study 6369594 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant immunotherapy with Corynebacterium parvum (4 mg/m2 divided among the four extremities in 1- to 2-week cycles)
Number of subjects: 136
Study 6369594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with DTIC and cyclophosphamide
Number of subjects: 136
Study 6369594 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant immunotherapy with Corynebacterium parvum
Number of subjects: 136
Study 31175052 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline chemotherapy (doxorubicin)
Number of subjects: 967
Study 31175052 — intervention group
Group type: COMPARATOR
Intervention: Non-anthracycline taxane chemotherapy
Number of subjects: 967
Study 29231163 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel lyophilized rapid-disintegrating tablet (bup-lyo)
Number of subjects: 3
Study 29231163 — intervention group
Group type: COMPARATOR
Intervention: Standard sublingual buprenorphine tablet (bup-SL)
Number of subjects: 3
Study 27099473 — intervention group
Group type: EXPERIMENTAL
Intervention: DLBS3233 at a dose of 50‐100 mg daily
Number of subjects: 80
Study 27099473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24872326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 45 P. falciparum-infected mosquitoes
Number of subjects: 29
Study 24872326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 30 P. falciparum-infected mosquitoes
Number of subjects: 29
Study 24872326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS immunization with bites from 15 P. falciparum-infected mosquitoes
Number of subjects: 29
Study 24872326 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS immunization
Number of subjects: 29
Study 22189065 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg of pyridoxine hydrochloride for 2 weeks
Number of subjects: 60
Study 22189065 — intervention group
Group type: COMPARATOR
Intervention: 1.28mg of pyridoxine hydrochloride for 2 weeks
Number of subjects: 60
Study 20597824 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 80
Study 17852827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day for 6 months
Number of subjects: 44
Study 17852827 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 44
Study 16061593 — intervention group
Group type: EXPERIMENTAL
Intervention: L-aspartic acid (6 doses per day, 5 mL per dose)
Number of subjects: 64
Study 16061593 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically hydrolyzed casein (EHC) (6 doses per day, 5 mL per dose)
Number of subjects: 64
Study 16061593 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey/casein (W/C) (6 doses per day, 5 mL per dose)
Number of subjects: 64
Study 16061593 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-glucuronidase inhibitors)
Number of subjects: 64
Study 16191239 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 16191239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10392734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 50
Study 10392734 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin
Number of subjects: 50
Study 8879847 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon 4.5 MU three times per week for 3 months
Number of subjects: 32
Study 8879847 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 32
Study 1726009 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine
Number of subjects: 12
Study 1726009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6388303 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 12
Study 30526230 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg twice daily for 12 weeks
Number of subjects: 88
Study 30526230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 27775818 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice a day
Number of subjects: 54
Study 27775818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 27029890 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered SEMS
Number of subjects: 43
Study 27029890 — intervention group
Group type: COMPARATOR
Intervention: Uncovered SEMS
Number of subjects: 43
Study 24470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 150 mg ER once daily under fasting conditions
Number of subjects: 24
Study 24470753 — intervention group
Group type: COMPARATOR
Intervention: Itopride 50 mg IR three times daily in fasting state
Number of subjects: 24
Study 24470753 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 150 mg ER once daily under fed conditions
Number of subjects: 24
Study 22392817 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of interleukin-6 (IL-6) soluble receptor (SR)
Number of subjects: 400
Study 22392817 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of tumor necrosis factor (TNF) SR1
Number of subjects: 400
Study 22392817 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of tumor necrosis factor (TNF) SR2
Number of subjects: 400
Study 22392817 — intervention group
Group type: EXPERIMENTAL
Intervention: All three markers in the highest quartile
Number of subjects: 400
Study 20547392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on the Taichong point
Number of subjects: 194
Study 20547392 — intervention group
Group type: COMPARATOR
Intervention: Placebo point acupressure
Number of subjects: 194
Study 17627164 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily for 4 weeks, then 20 mg as needed 2-3 hours before sexual activity for 4 months)
Number of subjects: 91
Study 17627164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine combined with sildenafil (50 mg as needed 1 hour before sexual activity for 4 months)
Number of subjects: 91
Study 15855258 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2; 2 mg, followed by 4 mg)
Number of subjects: 24
Study 15855258 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg, followed by 120 mg)
Number of subjects: 24
Study 15855258 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2)
Number of subjects: 24
Study 15855258 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 24
Study 15855258 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (E2) and Raloxifene
Number of subjects: 24
Study 11339909 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% vaginal clindamycin cream for 7 days
Number of subjects: 375
Study 11339909 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo cream for 7 days
Number of subjects: 375
Study 10374456 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily theophylline dosing (TD)
Number of subjects: 10
Study 10374456 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily theophylline dosing (OD)
Number of subjects: 10
Study 10374456 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 10
Study 7837152 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 19
Study 7837152 — intervention group
Group type: COMPARATOR
Intervention: Active disease
Number of subjects: 19
Study 3534593 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFPT (Cyclophosphamide, Methotrexate, 5-Fluorouracil plus Tamoxifen)
Number of subjects: 776
Study 3534593 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFP (Cyclophosphamide, Methotrexate, 5-Fluorouracil plus Prednisone)
Number of subjects: 776
Study 3534593 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) with Prednisone
Number of subjects: 776
Study 30166366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose alone or combined with maternal holding
Number of subjects: 80
Study 30166366 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed breast milk
Number of subjects: 80
Study 30166366 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 80
Study 30166366 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-infant relationship (combined with oral glucose and breastfeeding)
Number of subjects: 80
Study 27086734 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline-Rifampin (Group-A)
Number of subjects: 107
Study 27086734 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline-Rifampin-Levofloxacin (Group-B)
Number of subjects: 107
Study 24898579 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection
Number of subjects: 15
Study 24898579 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 15
Study 24898579 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BTA and saline
Number of subjects: 15
Study 24286965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (subcutaneous continuous monitoring system)
Number of subjects: 16
Study 24286965 — intervention group
Group type: COMPARATOR
Intervention: Capillary glucose monitoring (conventional group)
Number of subjects: 16
Study 21803657 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based memory training (6-week psychoeducation and strategy course)
Number of subjects: 31
Study 18098237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg ramipril
Number of subjects: 8
Study 18098237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16513902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in written format (ZSDS‐W)
Number of subjects: 71
Study 16513902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in American Sign Language format (ZSDS‐S)
Number of subjects: 71
Study 16513902 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Self‐Rated Depression Scale in written format (ZSDS‐W) and Hamilton Depression Scale (HAM‐D)
Number of subjects: 71
Study 12905095 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 g of CHO (HIGH)
Number of subjects: 7
Study 12905095 — intervention group
Group type: COMPARATOR
Intervention: 50 g of CHO (LOW)
Number of subjects: 7
Study 10711610 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic ofloxacin therapy (2x200 mg/d for 5 days) as adjunct to flap surgery
Number of subjects: 25
Study 10711610 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery only (control)
Number of subjects: 25
Study 9166195 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 0
Study 9166195 — intervention group
Group type: COMPARATOR
Intervention: Control (attempt to conserve the amniotic membranes)
Number of subjects: 0
Study 1294304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sugar clearance
Number of subjects: 22
Study 1294304 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with 0‐2 root caries lesions
Number of subjects: 22
Study 1294304 — intervention group
Group type: EXPERIMENTAL
Intervention: Long oral clearance time
Number of subjects: 22
Study 7040955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside intravenous infusion
Number of subjects: 328
Study 7040955 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment and infusion of 5% glucose (Control)
Number of subjects: 328
Study 30069803 — intervention group
Group type: EXPERIMENTAL
Intervention: Baobab diet (baobab seed meal)
Number of subjects: 30
Study 30069803 — intervention group
Group type: COMPARATOR
Intervention: Soybean diet (control)
Number of subjects: 30
Study 30069803 — intervention group
Group type: EXPERIMENTAL
Intervention: Vachellia diet (Vachellia polyacantha leaf-meal)
Number of subjects: 30
Study 30365584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% cream, applied topically twice daily for 5 days
Number of subjects: 0
Study 30365584 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 27107547 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered dilute diesel engine exhaust (DE)
Number of subjects: 26
Study 27107547 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered dilute diesel engine exhaust
Number of subjects: 26
Study 27107547 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 26
Study 24387048 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention by an Advanced Practice Nurse (APN) using case management and counseling techniques
Number of subjects: 340
Study 24387048 — intervention group
Group type: COMPARATOR
Intervention: Usual GP-care
Number of subjects: 340
Study 22258156 — intervention group
Group type: EXPERIMENTAL
Intervention: bihemispheric tDCS and simultaneous occupational/physical therapy during the first 5-day period
Number of subjects: 10
Study 22258156 — intervention group
Group type: EXPERIMENTAL
Intervention: bihemispheric tDCS and simultaneous occupational/physical therapy during the second 5-day period
Number of subjects: 10
Study 22258156 — intervention group
Group type: EXPERIMENTAL
Intervention: bihemispheric tDCS and simultaneous occupational/physical therapy over two periods
Number of subjects: 10
Study 19667033 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence‐based Practice for Improving Quality method (intervention group)
Number of subjects: 0
Study 19667033 — intervention group
Group type: COMPARATOR
Intervention: Control group (infection group)
Number of subjects: 0
Study 19667033 — intervention group
Group type: COMPARATOR
Intervention: Control group (pulmonary group)
Number of subjects: 0
Study 17237312 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean red meat intake (approximately 200 g/d)
Number of subjects: 60
Study 16847402 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1452 + rgp120
Number of subjects: 30
Study 16847402 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1452 alone
Number of subjects: 30
Study 16847402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12764338 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered tetracaine
Number of subjects: 60
Study 12764338 — intervention group
Group type: COMPARATOR
Intervention: Plain tetracaine
Number of subjects: 60
Study 12764338 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between buffered and plain tetracaine
Number of subjects: 60
Study 10368879 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6) - no drug treatment, only exercise training
Number of subjects: 18
Study 10368879 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment group (n=6) - previously treated with fluvastatin 20 mg/day
Number of subjects: 18
Study 10368879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n=6) - received fluvastatin 20 mg/day during training
Number of subjects: 18
Study 9050100 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine solution
Number of subjects: 0
Study 9050100 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 1908385 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerin
Number of subjects: 0
Study 1908385 — intervention group
Group type: COMPARATOR
Intervention: Sublingual nitroglycerin
Number of subjects: 0
Study 7046434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hydrochlorothiazide (25 to 50 mg twice a day) and furosemide (increased doses of 320 to 480 mg/day)
Number of subjects: 8
Study 7046434 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (160 to 240 mg/day)
Number of subjects: 8
Study 29627267 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management modules (SelMa) group (3 hours)
Number of subjects: 698
Study 29627267 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management modules (SelMa) lecture (1 hour)
Number of subjects: 698
Study 29627267 — intervention group
Group type: COMPARATOR
Intervention: Usual care (only disease-related education)
Number of subjects: 698
Study 27677662 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (53 patients, 74.6%)
Number of subjects: 100
Study 27677662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 100
Study 27677662 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gastric tube
Number of subjects: 100
Study 27677662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing changes for fungating tumors (26 patients, 36.6%)
Number of subjects: 100
Study 26178509 — intervention group
Group type: EXPERIMENTAL
Intervention: DN (docetaxel plus cisplatin)
Number of subjects: 124
Study 26178509 — intervention group
Group type: COMPARATOR
Intervention: FP (nedaplatin plus cisplatin)
Number of subjects: 124
Study 22720715 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/bovine-derived xenograft (BDX)
Number of subjects: 10
Study 22720715 — intervention group
Group type: COMPARATOR
Intervention: BDX/collagen membrane
Number of subjects: 10
Study 21992427 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) with rechargeable pulse generator
Number of subjects: 132
Study 21992427 — intervention group
Group type: COMPARATOR
Intervention: Re-operation
Number of subjects: 132
Study 18456649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (24 mg)
Number of subjects: 82
Study 18456649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 16041502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dental care protocol
Number of subjects: 34
Study 16041502 — intervention group
Group type: COMPARATOR
Intervention: Limited dental care
Number of subjects: 34
Study 12837434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 60
Study 12837434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 60
Study 12837434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12837434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (open-label phase)
Number of subjects: 60
Study 12837434 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (2 years follow-up)
Number of subjects: 60
Study 10890299 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Consequences Expectancy Increase (HC)
Number of subjects: 123
Study 10890299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Management Expectancy Challenge (MM)
Number of subjects: 123
Study 10890299 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 123